The adoption curve for human-relevant models is accelerating. For lab leaders, the question is no longer whether these technologies will reshape translational science; it's whether your lab will be positioned to participate. This article offers practical guidance on the operational, financial, and strategic decisions that lab leaders face when integrating organoid research into their workflows.
The workforce challenge: Your most pressing operational concern
The most significant barrier to broader adoption of organoid technologies isn't access to equipment or reagents—it's the people required to make these complex models work. Culturing 3D models requires highly specialized expertise, and the training timeline is substantial. As one core facility director put it: it can take a full year to train a technician to proficiency. Within six to eight months of completing that training, many realize their skills are in high demand elsewhere and move on to industry roles. In practical terms, nearly two years of institutional investment can disappear with a single resignation.
These workforce dynamics create downstream challenges for research teams. Many labs struggle to establish standard operating procedures that yield consistent results across different technicians. When everyone produces organoids with different phenotypes, sizes, and structures, reproducibility becomes impossible. Extended culture timelines compound these challenges with brain organoids requiring 60-90 days and retinal organoids taking up to six months. Losing a trained scientist midstream can disrupt months of work and delay entire programs.
Lab leaders are not powerless in the face of these constraints. One effective strategy is to invest in automation platforms that encode best practices into standardized, reproducible workflows. When expertise is captured in a system rather than residing with a single individual, progress is less vulnerable to staff turnover. It is also critical to account for the true cost of workforce churn. Understanding that each departure can represent years of lost time and resources can help justify upfront investments that reduce reliance on individual expertise.
Lab Quality Management Certificate
The Lab Quality Management certificate is more than training—it’s a professional advantage.
Gain critical skills and IACET-approved CEUs that make a measurable difference.
Finally, fostering a collaborative culture—where teams actively share protocols and lessons learned—can help distribute knowledge more evenly. As organoid research grows more complex, many scientists are recognizing that sustained success depends on shared expertise rather than isolated skill sets.
Rethinking how you calculate value
One of the most significant required mindset shifts is moving from cost-per-well calculations to value-based assessment. Comparing the direct cost of 3D culture to 2D culture will always favor the simpler approach—3D biology will never be as cheap as 2D biology. But this comparison misses the point entirely. People are starting to look at value rather than outright cost. If you can get more predictive data, how does that streamline your downstream workflows? Progressive organizations view their processes holistically. Adding human-relevant models may increase costs at one stage while dramatically reducing expenses elsewhere: less 2D culture, significantly reduced animal work, and more targeted clinical studies with better-defined patient populations.
Automation as infrastructure
Successful adoption of organoid technologies requires viewing automation not as just a capital expense, but as infrastructure—a foundational investment that enables everything else. The value proposition extends beyond labor savings. These systems preserve institutional knowledge by encoding best practices into reproducible workflows. When your expert technician leaves, their protocols remain embedded in the system. You can train the platform to be your best person at everything, and that expertise can then be transferred across sites regardless of personnel changes.
Interested in life sciences?
Traditional automation in biology has been complex, requiring engineers and specialized expertise that biologists don't typically possess. Emerging precision automation is designed differently, using language familiar from manual cell culture while delivering consistency and throughput that manual processes cannot achieve.
That said, recognizing automation's value and successfully implementing it are two different challenges. Budget limitations often top the list. Lab leaders should work with vendors to calculate return on investment, factoring in savings from reduced training time, decreased personnel turnover, and increased throughput. Legacy system integration can also pose hurdles, so it’s important to look for platforms designed to work within existing laboratory ecosystems rather than requiring complete workflow overhauls. For labs lacking in-house engineering expertise, seek out precision automation solutions built "by biologists, for biologists" that use familiar cell culture concepts rather than requiring specialized programming knowledge. Finally, change management remains critical. Involve end users early in the selection process and emphasize how automation will enhance rather than replace their scientific contributions.
Quality control becomes more complex at scale
As biology scales, it changes. Production processes impact biological outcomes in ways that 2D culture never prepared us for. Lab leaders must recognize that scaling organoid production requires dedicated attention to quality control. Lot control, batch consistency, and standardized testing protocols become essential.
This is an order of magnitude more complex than in 2D systems. Consider the well-documented cases of contamination and misidentification in traditional cell culture. In 3D biology, these risks are amplified by the inherent variability of complex biological systems.
To enhance quality control practices at scale, lab leaders should prioritize two key tactics. First, implement lot control and batch consistency protocols by considering services that grow organoids in single batches using the same operators and materials, with each batch tested together and accompanied by a certificate of analysis. This approach provides the consistency needed for high-throughput studies. Second, develop standardized testing protocols that account for the biological variability inherent in 3D systems. Unlike 2D culture, where cells behave predictably, production processes in 3D biology directly impact biological outcomes, requiring dedicated attention to how scaling affects your specific model systems.
The collaborative imperative
The complexity of organoid research has fostered an inspiringly collaborative culture. Researchers working with 3D models actively seek to learn from one another, share best practices, and understand where they can improve. There's recognition that no one can succeed alone in this space—it's simply too hard.
This collaborative spirit extends even to pharmaceutical companies. Consortia like IQ MPS bring together major pharma leaders to advance microphysiological systems in drug discovery and toxicity testing. For lab leaders, this environment presents opportunities to engage with standardization efforts, prioritize knowledge sharing, and learn from the broader community.
Positioning for what comes next
The integration of artificial intelligence into organoid research represents a technological advancement, while also signaling a fundamental shift in how we approach drug discovery and personalized medicine. As labs build their interpretive capacity and pharmaceutical companies learn to align 3D model data with their existing knowledge bases, the potential for truly predictive, human-relevant science becomes increasingly tangible.
The transition to human-relevant models is underway. The right tools are available. The question is no longer if labs will adapt, but how quickly they can get there. And those who move decisively will be best positioned to participate in what promises to be an incredibly exciting era for translational science.
